MARAVAI LIFESCIENCES HOLDINGS, INC.(MRVI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRVI at 24.4/100 on a 32-signal composite quality model, placing it at rank #2,696 of 2,961 stocks — the bottom half of the AI-ranked universe. MRVI scores in the top quartile across institutional flow (94.7). Areas of concern include revenue growth (6.8) and profitability (13.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MARAVAI LIFESCIENCES HOLDINGS, INC. reports quarterly revenue of $51.4M, net income of $-12.4M, free cash flow of $3.6M. Top institutional holders of MRVI by reported 13-F value include GTCR, BlackRock, BRAIDWELL, based on the most recent SEC filings. MRVI trades on the Nasdaq exchange and files with the SEC under CIK 1823239. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRVI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MARAVAI LIFESCIENCES HOLDINGS, INC. directly from SEC EDGAR.